Latest market price
97.35
+2.83+2.99%
Earnings
Up 3.0% — Earnings due 2026-11-04 — pre-report positioning.
Medium confidence
TA
Loading chart...
Snapshot
| Index | S&P 500 | P/E | 23.69 | EPS (ttm) | 4.11 | Insider Own | 0.31% | Shs Outstand | 190.74M | Perf Week | -0.09% |
| Market Cap | 18.57B | Forward P/E | 10.75 | EPS next Y | 9.06 | Insider Trans | -2.29% | Shs Float | 190.40M | Perf Month | 10.26% |
| Enterprise Value | 25.64B | PEG | 3.57 | EPS next Q | 1.88 | Short Float | 4.18% | Perf Quarter | 1.61% | ||
| Income | 807.00M | P/S | 2.18 | EPS this Y | 4.40% | Short Ratio | 3.77 | Perf Half Y | 17.76% | ||
| Sales | 8.51B | P/B | 1.47 | EPS next Y | 6.10% | ROA | 3.54% | Short Interest | 7.96M | Perf YTD | 8.26% |
| Book/sh | 66.23 | P/C | 45.29 | EPS next 5Y | 6.64% | ROE | 6.36% | 52W High | 103.70 -6.12% | Perf Year | -2.22% |
| Cash/sh | 2.15 | P/FCF | 10.15 | EPS past 3/5Y | 47.78% — | ROIC | 5.51% | 52W Low | 79.12 23.04% | Perf 3Y | -5.60% |
| Dividend Est. | 0.96 (0.99%) | EV/EBITDA | 10.97 | Sales past 3/5Y | 5.86% 6.08% | Gross Margin | 69.87% | Volatility | 2.34% 2.44% | Perf 5Y | -33.56% |
| Dividend TTM | 0.96 (0.99%) | EV/Sales | 3.01 | EPS Y/Y TTM | 0.00% | Oper. Margin | 15.73% | ATR (14) | 2.44 | Perf 10Y | -21.31% |
| Dividend Ex-Date | Sep 30, 2026 | Quick Ratio | 1.69 | Sales Y/Y TTM | 8.63% | Profit Margin | 9.48% | RSI (14) | 56.78 | Recom | 2.67 |
| Dividend Gr. 3/5Y | 0.00% 0.59% | Current Ratio | 1.69 | EPS Q/Q | 0.00% | SMA20 | 3.34% | Beta | 0.47 | Target Price | 104.14 |
| Payout | 23.35% | Debt/Eq | 0.59 | Sales Q/Q | 4.81% | SMA50 | 2.72% | Rel Volume | 1.25 | Prev Close | 94.52 |
| Employees | 17,000 | LT Debt/Eq | 0.50 | Earnings | Nov 04 | SMA200 | 6.19% | Avg Volume | 2.06M | Price | 97.35 |
| IPO Date | Jul 25, 2001 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 2.97% 1.97% | Net Debt/EBITDA | 3.03 | Volume | 2,578,938 | Change | 2.99% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-10-26 | Reiterated | Canaccord Genuity | Hold | $83 → $100 |
| Aug-06-26 | Reiterated | Robert W. Baird | $92 → $104 | |
| Aug-06-26 | Reiterated | UBS | Sell | $115 → $120 |
| Aug-06-26 | Reiterated | BMO Capital | Market Perform | $95 → $96 |
| Aug-06-26 | Reiterated | RBC Capital | Outperform | $111 → $110 |
| Aug-06-26 | Reiterated | Bernstein | Market Perform | $99 → $93 |
| Jul-28-26 | Reiterated | UBS | Sell | $89 → $115 |
| Jul-09-26 | Downgrade | BMO Capital | Outperform → Market Perform | $95 |
| Apr-29-26 | Reiterated | Canaccord Genuity | Hold | $93 → $83 |
| Apr-29-26 | Reiterated | Stifel Nicolaus | Buy | $110 → $105 |
Latest News· Times ET
Nov-02-26
Oct-29-26
10:41AM
07:30AM
Oct-26-26
Oct-21-26
Oct-14-26
Oct-13-26
Oct-13-2607:30AM
Oct-12-26
Oct-07-26
Oct-06-26
07:30AM
06:15AM
Sep-29-26
Sep-28-26
Sep-28-2608:31AM
Company
Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific. The Americas segment consists of the U.S. and includes other North, Central and South American markets. The Europe Middle East and Africa segment includes France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment refers to the key markets such as Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 8,509 | 8,232 | 7,679 | 7,394 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 2,563 | 3,160 | 2,191 | 2,084 | — | — | — | — | — | |
| Gross Profit | 5,946 | 5,072 | 5,487 | 5,310 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 3,427 | 3,251 | 2,930 | 2,839 | — | — | — | — | — | |
| Research and Development | 443 | 459 | 437 | 459 | — | — | — | — | — | |
| Other Operating Expense | 737 | 0 | 835 | 735 | — | — | — | — | — | |
| Operating Income | 1,338 | 1,362 | 1,286 | 1,278 | — | — | — | — | — | |
| Interest Expense | 289 | 293 | 218 | 201 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -116 | -239 | -31 | -9 | — | — | — | — | — | |
| Net Income Before Taxes | 933 | 831 | 1,037 | 1,067 | — | — | — | — | — | |
| Income Taxes | 127 | 126 | 131 | 42 | — | — | — | — | — | |
| Consolidated Net Income | 807 | 705 | 904 | 1,024 | — | — | — | — | — | |
| Net Income From Continuing Operations | 807 | 705 | 905 | 1,025 | — | — | — | — | — | |
| Net Income | 807 | 705 | 904 | 1,024 | — | — | — | — | — | |
| EPS (Recurring) | 4.13 | 3.56 | 4.45 | 4.91 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 4.13 | 3.56 | 4.45 | 4.91 | — | — | — | — | — | |
| EPS (Diluted) | 4.11 | 3.55 | 4.43 | 4.88 | — | — | — | — | — | |
| EBITDA | 2,337 | 2,217 | 2,251 | 2,220 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 23.69 | 25.33 | 23.84 | 24.94 | — | — | — | — | — | |
| Price To Sales Ratio | 2.20 | 2.16 | 2.79 | 3.44 | — | — | — | — | — | |
| Gross Margin | 69.88 | 61.61 | 71.45 | 71.81 | — | — | — | — | — | |
| Operating Margin | 15.72 | 16.55 | 16.75 | 17.28 | — | — | — | — | — | |
| Net Margin | 9.48 | 8.56 | 11.77 | 13.85 | — | — | — | — | — | |
| Shares Outstanding | 192 | 198 | 203 | 209 | — | — | — | — | — | |
| Market Capitalization | 18,691 | 17,804 | 21,443 | 25,435 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Campbell Gary Craig | President, Americas | Oct 01 '26 | Option Exercise | 0.00 | 3,586 | 0 | 2,654 | Oct 05 |
| Thornal Kevin R | Grp Pres-Global Business | Sep 11 '26 | Sale | 92.95 | 5,691 | 528,978 | 0 | Sep 15 |
| Phipps Chad F | See remarks below. | Sep 04 '26 | Sale | 98.35 | 3,000 | 295,050 | 65,231 | Sep 09 |
| Thornal Kevin R | Grp Pres-Global Business | Aug 01 '26 | Option Exercise | 0.00 | 9,957 | 0 | 9,957 | Aug 04 |
| Yi Sang | Group President, Asia Pacific | May 29 '26 | Sale | 82.64 | 5,000 | 413,216 | 27,251 | Jun 02 |
| Noor Jehanzeb | See remarks below. | Apr 01 '26 | Option Exercise | 0.00 | 6,626 | 0 | 6,828 | Apr 03 |
| Winkler Lori | SVP and CHRO | Mar 12 '26 | Sale | 94.66 | 2,650 | 250,849 | 10,224 | Mar 16 |
| Upadhyay Suketu | Exec VP, CFO | Mar 06 '26 | Option Exercise | 0.00 | 14,776 | 0 | 71,514 | Mar 10 |
| VAN ZUILEN WILFRED | Group Pres, EMEA | Mar 06 '26 | Option Exercise | 0.00 | 7,004 | 0 | 31,553 | Mar 10 |
| Winkler Lori | SVP and CHRO | Mar 06 '26 | Option Exercise | 0.00 | 5,634 | 0 | 13,503 | Mar 10 |
| Yi Sang | Group President, Asia Pacific | Mar 06 '26 | Option Exercise | 0.00 | 9,414 | 0 | 32,251 | Mar 10 |
| Stellato Paul A | VP, Controller, CAO | Mar 06 '26 | Option Exercise | 0.00 | 1,970 | 0 | 5,890 | Mar 10 |
| Phipps Chad F | See remarks below. | Mar 06 '26 | Option Exercise | 0.00 | 6,786 | 0 | 68,603 | Mar 10 |
| Tornos Ivan | Chairman, President and CEO | Mar 06 '26 | Option Exercise | 0.00 | 34,704 | 0 | 92,118 | Mar 10 |
| VAN ZUILEN WILFRED | Group Pres, EMEA | Feb 25 '26 | Option Exercise | 0.00 | 3,182 | 0 | 26,637 | Feb 27 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.